The Only Full Drug Lifecycle Company
Intelligence that accelerates
AI-enabled clinical trials powered by community physicians. Phase I–IV coverage across 13 strategic markets with 3.5× enrollment velocity.
The Uncomfortable Truth
THE
PROGRESS
ILLUSION
New entrants. New platforms. New contracts.
The same broken trial management process.
The industry invested in contracting speed, site portals, and decentralized tooling — but never fixed the core: who enrolls patients, how fast, and whether it holds across the next trial.
What the Industry Still Hasn't Fixed
The Unresolved Problem
Sites Are Still Inefficient at Scale
Hundreds of new site networks launched. The majority underenroll, miss timelines, and churn. Volume without performance is noise.
We Simplified Contracts — Not Outcomes
Streamlined MSAs and faster SIV scheduling created the feeling of progress. Enrollment velocity didn't follow. The bottleneck moved downstream.
No Repeatable Enrollment Engine Exists
Every trial restarts from zero. Site relationships, patient pipelines, protocol fit — rebuilt trial by trial, burning capital and compressing timelines.
Cost Per Patient Continues to Climb
Technology spend multiplied. Vendor layers deepened. Cost efficiency never materialized. The industry added complexity and called it innovation.
What still isn't solved: meaningful patient enrollment velocity, repeatable outcomes, and cost-efficient scale — delivered consistently, across therapeutic areas amongst community physicians that are representative of real world application and standard of care.
Who We Are
A team dedicated to revitalizing
the last generation of experienced PIs
A multi-disciplinary team with breadth of knowledge across every therapeutic area we serve.
Culture of Collaboration
A multi-disciplinary team with breadth of knowledge and expertise across several therapeutic areas. Our integrated model gives you the advantage of early and ongoing insight throughout trial management and execution.
Commitment to Quality
Exceeding study-specific milestones through streamlined operational workflows and a centralized analytics platform. Our data-driven approach ensures precision without sacrificing speed.
Patient Centricity
Patient-centric study protocols for recruitment and trial engagement. We ensure inclusive representation and accessible clinical trials among diverse populations.
Technology Forward
AI-driven patient identification, real-time study progress dashboards, and operational automation tools that improve speed and efficiency without compromising accuracy.
What We Do
Areas of
Therapeutic Expertise
Four core TAs. Deep domain knowledge across every one.
Cardiovascular
Deep access to cardiovascular outcomes trial (CVOT) patient populations. Our network spans in-patient cardiology practices with direct referral pipelines across all phases.
CNS, Behavioral Health, Neurology
Addressing progressive neurological conditions and psychiatric indications requiring long-term follow-up. Digital phenotyping capabilities and innovative trial designs for complex CNS protocols.
Cell & Gene Therapy, CAR-T
The only integrated research network built to support high-complexity cell and gene therapy protocols across all phases — with deep expertise in CAR-T design and regulatory navigation.
Endocrine, Metabolic, GI
Direct access to patients with specialized focus on metabolic disease, MASH diagnostics, and GI conditions. Our network spans providers across endocrinology and gastroenterology.
Driven by a passion for excellence in complex therapeutic areas
The Vitra Advantage
Not Just a Network.
A Research Organization.
Every role at Vitra carries deep therapeutic expertise — PI, coordinator, recruiter, nurse, regulatory. We operate inside medical practice, not alongside it.
PIs Who Live Inside the Therapeutic Area
Our principal investigators are practicing clinicians with longitudinal patient relationships in the exact therapeutic areas we operate — bringing referral networks, disease familiarity, and patient trust that no site activation platform can replicate.
PRACTICE-EMBEDDEDEvery Role Carries Therapeutic Intelligence
Coordinators, nurses, recruiters, and regulatory staff are hired against specific therapeutic areas — not as generalists rotating across disease states. When a recruiter screens a patient, they understand the protocol because they understand the disease.
TA-SPECIFIC STAFFINGResearch and Practice as a Single Operating Unit
We don't append research to a practice — we are woven into it. Trial participants are also standard-of-care patients. That continuity creates enrollment pipelines, reduces dropout, and produces real-world data with direct clinical relevance.
INTEGRATED MODELWe Automate What Should Be Automated. Nothing More.
Others automate because they lack the expertise to know what requires human judgment. We automate administrative burden and preserve human intelligence where it drives outcomes: patient conversations, protocol fit, and site decision-making.
PRECISION-FIRSTFull Drug Lifecycle · How Vitra Works
The only partner spanning every stage.
Safety & Dosing
Infusion center with overnight accommodation. Purpose-built for early-phase complexity, flexible sponsor protocols, and rapid site activation.
Proof of Concept
AI-matched enrollment into high-prevalence geographies. Pre-identified patient cohorts compress screening timelines significantly.
Scale & Validate
3.5× enrollment velocity. 99% patient retention. 15× fewer protocol deviations. No surprises at FDA submission.
Safety Monitoring
Pharmacovigilance within the same site network. No new relationships, no ramp-up. Continuous outcomes tracking post-approval.
FDA Approval
Data quality and enrollment velocity directly compress time-to-approval. Zero data-integrity rejections across all trials ever managed.
Real-World Evidence
EHR-integrated across our physician network. Longitudinal outcomes data powering label expansions, payer submissions, and reimbursement decisions.
Site Performance Analysis · Phase I–IV
Quality holds.
Scale proves it.
Trial after trial.
Most sites accumulate deviations the moment enrollment accelerates. Vitra's PIs don't. As volume climbs, our infrastructure holds — and the gap between what we deliver and what the industry accepts widens with every patient enrolled.
Cumulative Patient Enrollment
Vitra-Managed Sites vs. Industry Average · Weeks 0–24
Patient Retention Rate
Vitra vs. Community-Recruited Sites · Phase I–IV
Protocol Deviations vs. Patients Randomized
Vitra-Managed Sites vs. Community Sites
Live Operations · Clinical Intelligence Platform
Real-Time Visibility.
Total Control.
Every trial, every site.
Our sponsors don't wait for monthly reports. Vitra's operations dashboard delivers real-time enrollment tracking, site performance scoring, and quality metrics — the same intelligence our internal team uses to run the network.
| Study ID | Trial Name | Phase | Status | Sites | Enrollment | Progress |
|---|
The Feedback Has Been Consistent
Vitra-managed sites outperform other sites
in all aspects of trial management.
How We Operate
Not Task-Driven.
Process-Built.
Each process at Vitra functions like a mini-company — its own people, its own accountability, its own culture of improvement.
People-First Organization
Roles are deeply understood — from sponsor liaisons to PIs, every function knows its domain.
Continuous Improvement
We improve what others have left unchanged for decades — not by adding tools, but by redesigning process.
Network of Mini-Companies
Each process is a self-contained operating unit — accountable, measurable, and scalable independently.
Four Core Processes
Each one a domain unto itself.
Site Activation SPONSOR-FACING
Rapid network activation driven by a dedicated centralized startup team and AI-powered site-trial matching. Purpose-built to eliminate the #1 delay in trial initiation.
Avg. activation 5× faster than industry standardPatient Enrollment PATIENT-FACING
Pre-identified patient cohorts accelerate first-patient-enrolled timelines. Inclusive recruitment protocols built for diverse populations across all therapeutic areas.
3.5× faster enrollment vs. community sites at Week 24Trial Execution CRO-INTEGRATED
Streamlined operational workflows with real-time study progress monitoring and centralized data management. Coordinators own fewer studies — and own them deeper.
Standardized SOPs across Phase I–IV and cell & gene programsQuality Assurance INTERNALLY DRIVEN
Self-initiated quality audits mirror enrollment pace — ensuring IMVs yield no major deviations throughout trial conduct. QA is a standing team, not a project response.
15× fewer protocol deviations vs. community sites at 100 patientsThe Vitra Difference
We are veterans who improve what others have left unchanged for decades — not technologists layering tools on broken process. Every role carries institutional depth and the mandate to make it better.
Geographic Site Network · Market Selection Rationale
Where the Patients Are. That's Where We Operate.
Site Strategy
Not every city.
The right cities
—
with the right patients.
Every site is where community physicians already carry the patient relationships and referral trust that academic sites spend years building.
Geography is enrollment strategy, diversity strategy, and RWE strategy — all at once.
SOUTHEAST 3 MARKETS
South Florida
44% Hispanic + Black population. Fastest-growing 65+ cohort. All 4 TAs enrollable from a single corridor.
Tampa Bay
27% Hispanic pop with high T2D burden. Fastest NASH + GLP-1 enrollment in FL.
Orlando
Most ethnically diverse FL metro. Rare Spanish-speaking psych cohort. High MDD + PTSD unmet need.
MID-ATLANTIC 4 MARKETS
Baltimore
62% Black population — critical for CV + psych FDA diversity mandates.
Washington DC
Chronically underrepresented despite extreme disease burden. Federal advocacy infrastructure.
Richmond
40% Black pop — highest metabolic co-morbidity in VA. Dual psych + metabolic co-enrollment opportunity.
Philadelphia
44% Black population — highest minority hematology trial access in the Northeast. Community oncology.
NORTHEAST · MIDWEST · WEST 6 MARKETS
Pittsburgh
Top Alzheimer's + Parkinson's market in Mid-Atlantic. Academic-adjacent without overhead.
Newark
NYC patient flow without NYC costs. High co-occurring T2D + depression. Strong Haitian + Dominican access.
Milwaukee
One of the most underrepresented CV markets in US trials. Community physician relationships bypass barriers.
Phoenix
43% Hispanic pop — Spanish-speaking Alzheimer's + metabolic cohorts. Snowbird influx expands enrollment windows.
Seattle
Fred Hutch + UW ecosystem. 19% Asian pop — rare access to Asian hematology cohorts underrepresented in CAR-T.
Tucson
Tohono O'odham + Pascua Yaqui tribal access — highest T2D prevalence globally. Unique population.
Network Diversity Profile
Built for the Patients Most Trials Miss.
Our site network is concentrated in geographies where minority, Hispanic, and underserved populations represent the majority — creating diversity enrollment access that purpose-built academic networks cannot replicate.
FDA Diversity Action Plans (2024) now require sponsors to actively enroll underrepresented populations. Every Vitra market was selected to make compliance a structural feature — not an afterthought.
Per-Market Diversity Breakdown
The standard
has changed.
Have you?
The sponsors running the most important trials in medicine no longer accept slow activation, unpredictable enrollment, or sites that treat quality as optional. They've found a network that doesn't. And they don't go back.
Get In Touch
contact@vitraclinical.com
vitraclinical.com · Boynton Beach, FL
Every week you wait is a week of avoidable delay — a week another patient didn't enroll.
We built Vitra because the industry deserved a site network that takes the work as seriously as the science. One conversation is all it takes to see what that means in practice.
What Happens Next
Start the Conversation